| Old Articles: <Older 5001-5010 Newer> |
|---|
 |
Chemistry World
August 2008 |
Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?   |
American Journal of Nursing
August 2008 |
Compliance with Hand Hygiene Guidelines: Where Are we in 2008? Hospitals may best improve hand hygiene among its staff by assessing the barriers to it, measuring the rates of compliance, educating staff on the importance of hand hygiene, making sanitizing products more available for staff use, and holding staff accountable. |
The Motley Fool
July 31, 2008
Brian Lawler |
Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it? |
The Motley Fool
July 30, 2008
Brian Orelli |
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. |
Chemistry World
July 28, 2008
Rebecca Trager |
Ranbaxy troubles place FDA under fire Indian drug firm Ranbaxy is facing scrutiny by American federal agencies and lawmakers over allegations that the company falsified scientific evidence to gain US approval for its products. |
The Motley Fool
July 28, 2008
Brian Lawler |
Amgen's Bone-Building Boost The drugmaker gets good news about a top pipeline compound. |
Chemistry World
July 25, 2008
Sarah Houlton |
Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding. |
The Motley Fool
July 25, 2008
Brian Lawler |
Glaxo Changes Course Will a shift in strategy turn the drugmaker around? |
The Motley Fool
July 25, 2008
Brian Orelli |
Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out. |
The Motley Fool
July 25, 2008
Brian Orelli |
Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug. |
| <Older 5001-5010 Newer> Return to current articles. |
